



RED LIGHT HOLLAND

RED LIGHT HOLLAND CORP.

Management's Discussion & Analysis

For the three and nine months ended December 31, 2023 and 2022

**RED LIGHT HOLLAND CORP.
MANAGEMENT’S DISCUSSION AND ANALYSIS
FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2023 AND 2022**

This management’s discussion and analysis (this “MD&A”) was prepared as of February 29, 2024 and is provided to assist readers in understanding Red Light Holland Corp.’s financial performance for the three and nine months ended December 31, 2023. It should be read in conjunction with the unaudited condensed interim consolidated financial statements for the period ended December 31, 2023 (the “Interim Financial Statements”) and the audited consolidated financial statements for the fiscal years ended March 31, 2023 and 2022, together with the notes thereto (the “Annual Financial Statements”) and the management’s discussion and analysis prepared in conjunction with the Annual Financial Statements (the “Annual MD&A”). This MD&A has been prepared in compliance with section 2.2.1 of Form 51-102F1, in accordance with National Instrument 51-102 – *Continuous Disclosure Obligations*. The results reported herein have been derived from the Interim Financial Statements and Annual Financial Statements, prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (the “IASB”) and, unless otherwise indicated, are presented in Canadian dollars.

Unless the context otherwise requires, use in this MD&A of the “Company”, “Red Light Holland”, “RLHC”, “we”, “us”, or “our” means Red Light Holland Corp. and its subsidiaries.

The Company’s common shares (“Common Shares”) trade on the Canadian Stock Exchange (“CSE”) under the symbol ‘TRIP’, on the Frankfurt Stock Exchange under the symbol “4YX” and on the OTCQB Venture Market (the “OTCQB”) under the symbol ‘TRUFF’. Additional information relating to RLHC is available at <http://www.sedarplus.ca/>.

For the purposes of preparing this MD&A, management, in conjunction with the board of directors of the Company (the “Board”), considers the materiality of information. Information is considered material if: (i) such information results in, or would reasonably be expected to result in, a significant change in the market price or value of the Common Shares; or (ii) there is a substantial likelihood that a reasonable investor would consider it important in making an investment decision; or (iii) it would significantly alter the total mix of information available to investors. Management, in conjunction with the Board, evaluates materiality with reference to all relevant circumstances, including potential market sensitivity.

The Board approves the Interim Financial Statements and this MD&A and ensures that the Company’s officers have discharged their financial responsibilities. The Board’s review is accomplished principally through the audit committee of the Company, which reviews and recommends all financial reports to the Board for approval prior to filing.

This MD&A contains forward-looking information and statements (collectively, “FLS”). See the section “Caution Regarding Forward-Looking Information and Statements” for a discussion of the risks, uncertainties and assumptions relating to those statements.

COMPANY OVERVIEW

The Company is an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.

CONSOLIDATED STATEMENTS OF NET LOSS

(Unaudited)	Three months ended		Nine months ended	
	Dec 31		Dec 31	
	2023	2022	2023	2022
Revenue	1,291,070	1,175,235	3,476,072	2,696,749
Cost of sales	744,671	588,081	1,961,908	1,532,742
Gross profit	546,399	587,154	1,514,164	1,164,007
<i>Gross profit as a % of sales</i>	42.3%	50.0%	43.6%	43.2%
General and administrative	1,713,185	1,703,606	4,718,690	4,258,220
Share based payments	155,827	87,509	1,222,136	516,795
Interest expense	71,893	8,673	178,697	19,153
Research	2,159	112,841	48,245	344,737
Loss before other items and taxes	(1,396,665)	(1,325,475)	(4,653,604)	(3,974,898)
Realized loss on sale of marketable securities	-	-	-	(19,364)
Change in fair value of marketable securities	4,159	(99,336)	(32,867)	(346,191)
Realized gain on sale of property, plant and equipment	-	-	13,138	-
Reversal of provision for sales tax receivable	-	205,636	-	205,636
Change in fair value of convertible debenture	-	(46,759)	-	(56,711)
Change in fair value of derivative liability	11,037	-	38,405	-
Change in fair value of call option	-	358	(28,110)	(1,760)
Change in fair value of contingent consideration	-	(158,345)	-	-
Foreign exchange (loss) gain	(2,719)	(4,579)	(746)	(9,183)
Interest income	135,689	54,725	399,931	106,836
Loss before taxes	(1,248,499)	(1,373,775)	(4,263,853)	(4,301,600)
Recovery of income taxes	28,932	61,429	58,700	148,758
Net loss	(1,219,567)	(1,312,346)	(4,205,153)	(4,152,842)
Net loss attributable to:				
Shareholders of Red Light Holland Corp.	(1,193,397)	(1,305,436)	(4,136,373)	(4,072,769)
Non-controlling interests	(26,170)	(6,910)	(68,780)	(80,073)
Net loss	(1,219,567)	(1,312,346)	(4,205,153)	(4,152,842)
Loss per share (basic and diluted)	(0.00)	(0.00)	(0.01)	(0.01)
Weighted average Common Shares outstanding	394,404,102	378,439,289	394,175,587	376,812,501

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(Unaudited)	Dec 31 2023	Mar 31 2023
Cash and cash equivalents	15,418,931	18,486,644
Accounts receivable	529,504	518,146
Sales tax receivable	463,629	283,397
Income tax receivable	35,738	81,652
Marketable securities	12,631	45,498
Prepaid expenses and deposits	2,090,569	2,051,361
Inventory	943,375	741,249
Total Current Assets	19,494,377	22,207,947
Property, plant and equipment	5,106,542	4,806,140
Marketable securities – non-current	865,268	865,268
Right of use assets	439,776	581,932
Call option	-	28,110
Intangible assets	125,468	339,352
Goodwill	1,308,779	1,314,534
Total Assets	27,340,210	30,143,283
Accounts payable and accrued liabilities	1,554,139	1,292,333
Loans and advances	905,059	905,059
Convertible debenture	320,275	257,695
Derivative liability	9,971	48,376
Lease liability – current portion	139,509	179,819
Total Current Liabilities	2,928,953	2,683,282
Lease liability	324,827	422,618
Contingent consideration	38,077	188,077
Deferred tax liability	449,734	506,476
Total Liabilities	3,741,591	3,800,453
Total Shareholders' Equity	23,598,619	26,342,830
Total Liabilities and Shareholders' Equity	27,340,210	30,143,283

SUMMARY OF THE QUARTER ENDED DECEMBER 31, 2023

Red Light Holland is engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.

We are focused on ramping up mushroom production, increasing distribution channels and growing our truffle/functional mushroom brands, consumer packaged goods and, recently announced, fresh mushrooms to drive increased sales while being determined to grow both our business-to-business retail sales and direct-to-consumer business via brick-and-mortar shops and the online sales of all products.

During the three months ended December 31, 2023, we focused on enhancing our existing business operations, explored new acquisitions, entered new sales channels, and made progress on the vertical integration of our operations.

Highlights of Key Events for the three months ended December 31, 2023

On October 19, 2023 the Company announced Red Light Holland's subsidiary, Radix Motion, received a patent issue date of November 7, 2023 for its 3D Movement Data and AI Innovations patent application. Radix Motion's research is directed to the use of human movement data in psychedelic-assisted therapy, including as a tool to promote positive experiences, to predict and personalize individual patient experiences, and to evaluate the efficacy of the therapy.

On November 2, 2023 the Company announced that it has engaged Dr. Taras Nahirny as Medical Advisor to help with the distribution of the company's homogenized psilocybin microdosing capsules. The Company also granted options to purchase an aggregate of 2,050,000 Common Shares of the Company to certain officers and consultants of the Company. The stock options are exercisable at a price of \$0.055 per share until October 30, 2028. Subject to rounding, 683,333 stock options will vest on April 30, 2023, 683,333 stock options will vest on October 30, 2024, and 683,333 stock options will vest on April 30, 2025.

On November 3, 2023 the Company announced that it has appointed Troy DuFour as Vice President of Sales.

On November 14, 2023 the Company announced that it has re-engaged former Health Minister Tony Clement as Senior Advisor to Advisory Board.

On November 13, 2023 and December 11, 2023, respectively, the Company announced that CCrest Laboratories have completed the four and five month stability tests for Red Light Holland's psilocybin microdosing capsules. The stability tests are aimed at determining the microdosing capsule's shelf life. The tests confirmed the capsules maintain the required amount of psychoactive compounds at these respective points in time. On January 23, 2024, the Company

clarified that after evaluation of test data, the shelf life for the capsules was determined to be four months.

Highlights of Key Events for the nine months ended December 31, 2023

On April 4, 2023 the Company announced that their subsidiary, AEM Farms in New Brunswick ("AEM Farms"), expanded their distribution of their Shiitake Mushroom to over 100 retail locations across Canada, including 47 Farm Boy markets across Ontario and all Loblaws and Your Independent Grocer (YIG) supermarkets in Ottawa, as well as all Costco locations in Ottawa and Gatineau and Whole Foods markets in Ottawa.

On April 5, 2023, the company issued 952,380 Common Shares and 238,095 warrants as a conversion of debentures.

On April 10, 2023, 984,305 RSUs vested and were issued.

On April 21, 2023 the Company received a Certificate of Analysis for its dehydrated homogenized natural psilocybin developed and tested by partner CCrest Laboratories aimed for distribution with NUBU Pharmaceuticals in Australasia. The Certificate of Analysis was issued for processed psilocybin truffles imported from Red Light Holland's farm in the Netherlands by CCrest Laboratories.

On April 24, 2023 the Company's Board of Directors approved the granting of 18,135,000 Options, with an exercise price of \$0.10 per option, and 5,975,000 Restricted Share Units ("RSUs") to Directors, Officers, employees and consultants of the Company. A total amount of 2,175,000 RSUs vested upon grant and were exercised into Common Shares. The options and RSUs vest on the following terms:

Participant	#	Vesting Terms
Options		
Directors, Officers and Consultants	14,800,000	1/3 upon grant; 1/3 after 12 months; 1/3 after 24 months from the issuance date
Employees and Consultants	2,135,000	Immediate upon grant
Consultants	1,200,000	1/6 after each of 3 months, 6 months, 9 months, 12 months, 15 months and 18 months from the issuance date
RSUs		
Directors and Officers	4,950,000	1/3 upon grant; 1/3 after 12 months; 1/3 after 24 months from the issuance date
Consultants	1,000,000	1/2 upon grant; 1/4 after 12 months; 1/4 after 24 months from the issuance date
Consultants	25,000	Immediate upon grant

On April 25, 2023, the Company announced that it has engaged media personality, Mia Khalifa as an Advisor of the Company. On October 10, 2023 the Company announced that it has terminated its association with Mia Khalifa.

On April 26, 2023 the Company published a report on psilocybin microdosing, called a Basic Guide to Microdosing, in Collaboration with NUBU Pharmaceuticals aimed At NUBU's Pharmaceutical's Network of Medical Doctors in Australasia. The report is aimed at educating law makers and a network of medical doctors in Australasia, about the potential benefits of microdosing psilocybin, based on the latest scientific research.

On May 18, 2023 a total of 200,000 warrants were exercised for gross proceeds of \$12,000.

On May 26, 2023 a total of 1,500,000 options were excessive for gross proceeds of \$90,000.

On June 1, 2023 Radix Motion, a fully owned technology subsidiary of Red Light Holland announced that further to its press release dated January 31, 2023, its U.S. "continuation-in-part" (CIP) application has been granted the right to participate in the "Patent Prosecution Highway" program and accorded "special" status. The Patent Prosecution Highway (PPH) is a fast-track examination procedure that allows applicants to reach final disposition of a patent application more quickly and efficiently than standard examination processing. As applications examined under the PPH program have a higher likelihood of allowance, it is hoped this decision will swiftly lead to an issued patent in the U.S., and subsequently in other PPH jurisdictions where a PPH request is also granted.

Radix Motion's claims are directed to the use of human movement data in psychedelic-assisted therapy, including as a tool to promote positive experiences, to prevent negative experiences, to predict and personalize individual patient experiences, and to evaluate the efficacy of the therapy. The patent application also covers Radix Motion's technology on the use of real-time analysis of human movement data to identify the position and body movement of a psychedelic facilitator or therapist to detect if a potential violation is occurring and activate real time alerts and safety measures. This technology does not require sending or storing any video information and helps to protect patient privacy. With this new technology, Radix Motion is leading the way in creating safer and more private psychedelic therapy sessions for clients.

On June 16, 2023 the Company announced that Happy Caps home grow kits are now available in 36 Canadian Tire stores and are now available in 110 retail stores in Canada. In addition, the Company satisfied certain earn-out obligation pursuant to the terms of the Acquisition Agreement (as defined in the June 10, 2021 press release) through the issuance of an aggregate of 1,543,208 Common Shares at a deemed price of \$0.0972 per common share, which are subject to the statutory hold period of four months and one day hold.

On June 19, 2023, the Company announced that CCrest Laboratories Inc., a Montreal-based cGMP pharmaceutical laboratory that holds a Controlled Drugs & Substances Dealer's License from Health Canada, has finished encapsulation of Red Light Holland's Natural Psilocybin grown in the

Netherlands that were imported to Canada under a Health Canada license and began stability testing. See under the heading “*Psilocybin Microdosing Capsules*” for additional discussion.

On June 27, 2023 the Company’s Board of Directors authorized the repurchase under a normal course issuer bid (“NCIB”) of up to 19,762,354 Common Shares from time to time over the next 12 months, through the facilities of the Canadian Securities Exchange or alternative trading systems, at prevailing market prices in order to allow the Company to use its excess cash reserves to strategically return value to shareholders. Purchase under the NCIB may commence as of July 4, 2023 and will end on the earlier of: (i) July 24, 2024, or (ii) the date on which the Company has purchased the maximum number of Common Shares to be acquired under the NCIB. The Company may terminate the NCIB earlier if it feels it is appropriate to do so.

The NCIB does not obligate the Company to purchase any Common Shares. If management decides it has a better use for its cash reserves, it is under no obligation to continue to purchase Common Shares and share purchases may be suspended or terminated at any time at the Company's discretion. The Company appointed Canaccord Genuity Corp. to conduct the NCIB. The purchase and payment of the Common Shares will be made in accordance with the requirements of the CSE and applicable securities laws. The Company will purchase Common Shares through the facilities of the CSE or alternative trading systems, at the prevailing market price on the CSE at the time of purchase, subject to limitations imposed by applicable securities laws. The actual number of Common Shares purchased, timing of purchases and share price will depend upon market conditions at the time and securities law requirements. All Common Shares acquired will be returned to treasury and cancelled.

On July 25, 2023 the Company announced the official launch of its partnership with Mistercap, LLC as www.mistercap.com went live for global consumers. The partnership created by Red Light Holland and Mistercap, LLC for the mushrooms and wellness brand called MISTERCAP commenced the sale of functional mushroom kits across North America during August 2023 with sales in Europe expected in the near term (originally stated October 2023). The European launch has experienced some delays related to supply chain logistics but is expected to launch through grocery retail in the European region early in calendar 2024.

On August 1, 2023 the Company announced the completion of all tests and procedures required for a full certificate of analysis of the capsules developed from Red Light Holland’s psilocybin truffles which are grown in their farm in the Netherlands and imported to Canada under a Health Canada approved psilocybin import license. The tests have confirmed that there are no pesticides or heavy metals in the capsules and that they are free from biocontainment. The testing was performed at CCrest Laboratories Inc. (“CCrest Laboratories”), a Montreal based cGMP pharmaceutical laboratory that holds a Controlled Drugs & Substances Dealer’s License from Health Canada.

Further to the above, on August 22, 2023 the Company announced that CCrest Laboratories have finished the first stages of stability testing the Red Light Holland’s natural psilocybin microdosing capsules. The stability tests were completed after 6 and 8 weeks of storage and are aimed at determining the microdosing capsule’s shelf life. The tests confirmed the capsules maintain the

required amount of psychoactive compounds (psilocybin and psilocin) at these respective points in time.

On August 8, 2023 the Company announced that their subsidiary Happy Caps Mushroom Farm ("Happy Caps") has expanded the future distribution of their mushroom home grow kits to over 135 retail stores in Canada, including 31 Longo's locations in southern Ontario commencing during September 2023.

On September 5, 2023 the Company announced the completion of the design phase of its 65,000 square foot mushroom farm through the submission of the permit application to the Township of Cavan-Monaghan. Further updates on the Peterborough Farm can be found below under the section "*Update on Operations and Significant Projects*".

On September 19, 2023 the Company announced the official launch of the Mistercap brand of grow at home mushroom kits.

UPDATE ON OPERATIONS AND SIGNIFICANT PROJECTS

The Company expanded its operations internationally and now has operations in the Netherlands, Canada and the United States of America. With the view of further expansion, the Company is closely and continuously looking for viable opportunities to expand operations of functional mushroom production and distribution as well as psilocybin production and sales across both North America and the European Union if and when regulations permit. The Company also has plans to expand operations into other geographical regions should regulations permit.

The following is an update on our current significant projects:

Netherlands

Retail Stores:

The Company's renovations and rebrand of its retail stores in Oss and Utrecht were completed earlier this fiscal year. We continue to increase the number of products sold through these locations to align the brand to the holistic view of mind and body health while executing on customer experience initiatives. With the completion of the aforementioned rebrand, the Company considers itself to be fully vertically integrated as the Company is able to produce, package, distribute and sell its own brand of truffles directly to customers, while continuously introducing new health and wellness products, through both brick-and-mortar retail shops and online.

Psilocybin Truffles:

The Company's Maka magic truffles line, including the Hollandia, Makanaut, Muskoka, Mexicana, Atlantis, Double Vision, Old Dutch and Utopia varieties, are designated as a Responsible Use Psychedelic. The Maka line of truffles is currently being distributed through SR Wholesale B.V., the Company's wholly owned subsidiary ("SR Wholesale"), and sold by a number of SmartShops across the Netherlands including our two retail stores located in Oss and Utrecht.

The Company's iMicrodose truffle line, including Minfuli, Triniti, Uniti, and Original, continues to be supported by the iMicroapp tele-counseling platform with over 900 registered users who agreed to share their anonymous data for research and receive access to the company's licensed therapist.

SR Wholesale:

Operationally, SR Wholesale experienced its best year-to-date results since its date of acquisition. The increase in sales and gross profit attributed to SR Wholesale was as a result of an increase in tourism in the Netherlands and efforts into expanding both product lines and distribution channels.

MiniChamp:

Earlier this fiscal year MiniChamp redesigned and rebranded its line of mushroom homegrow kits products. They are also secured an order with a German distributor to co-package and white label

80,000 mushroom home grow kits over the next 52 weeks. The first shipment was delivered in February 2024.

Canada

The Peterborough Farm:

During the quarter ended December 31, 2023, the Company received the building permit from the Township of Cavan-Monaghan for its 80,000 square foot mushroom farm. The Company has also started to coordinate and get quotes from companies and trades who will be involved in the early stages of the project as continued road work, excavation and footings/foundation work is anticipated to commence starting early calendar 2024. A significant portion of the operational equipment is being designed and manufactured in Europe and the Company will secure the orders with deposits in the near future. The Company expects to integrate into the community including looking for future employment from local personnel at the facility.

Once completed, the Peterborough Farm is expected to immediately generate revenues of approximately \$80,000 per week. As it ramps up to its full production capacity, the Company expects a revenue run rate of approximately \$16.0 to \$17.0 million per annum with strong profit margins and cash flows from operations.

The ability of the Peterborough Farm to immediately generate revenues of approximately \$80,000 per week and a future run rate of approximately \$16.0 to \$17.0 million per annum with strong profit margins and cash flow from operations is dependent on certain assumptions that management of the Company believes to be reasonable based on the information currently available to management, including the following assumptions: (a) the ability of the mushroom farm design firm in the Netherlands to develop sufficient plans needed for permit applications (b) the ability of the Company to receive the necessary permits from the Township of Cavan-Monaghan (c) the ability of the Company to finance the construction of the facilities following the grant of the permits (d) the ability of the Company to address unexpected setbacks which may delay the construction of the facilities (e) the growth process in respect of its production schedule being adequate to support the anticipated yield of mushrooms (f) the employees who cultivate, harvest, package and deliver to market the mushrooms on a timely basis are able to hire and capable to do so; (g) the expected yield of the Peterborough Farm provides an adequate basis for the production of new mushrooms; and (h) the current wholesale market for mushrooms will be able to absorb the additional production.

The facilities, as of the date of the MD&A, should take approximately 9 months to construct. The Company is awaiting the delivery dates from the overseas manufacturers that are constructing the production equipment. The cost to build the Mushroom Facilities is budgeted around \$12.0 million (previously reported \$8.0 million) which is contingent on permit approvals for the plans. The increased build costs represent facility design changes which will allow for future growth by investing in construction costs today that will allow for production scalability and expansion in the future.

The New Brunswick Farm:

As of the date of this MD&A, the AEM farm in New Brunswick is operating at 80-90 percent capacity and expects to be producing approximately 4,000 to 5,000 pounds of shiitake mushrooms per week on a go-forward basis, generating approximately \$24,000 and \$30,000 of revenue per week.

The Happy Caps Farm:

Earlier in the fiscal year, Happy Caps mushroom home grow kits were made available in 31 Longo stores across southern Ontario, increasing points of sales with a plan to add additional locations in the near term future. With the addition of the new Longo locations, Happy Caps Home Grow Mushroom Kits, as of the date of this MD&A, are now available in over 135 retail stores in Canada. In addition to these direct retail channels, Happy Caps is partnered with Van Noorts in a wholesale supply agreement, increasing our market presence in Canada.

Earlier in the fiscal year, the production of Happy Caps mushroom kits have officially been moved from our leased facility in Halifax to a third party facility in Ontario. The Halifax lease ended in January 2024 and the new production in Ontario is sourced through one of our farming partners. This change will result in our ability to increase production at a reduced cost per unit and allow for future scalability to meet increased demand.

Psilocybin Microdosing Capsules:

As of the date of this MD&A, the Company, in collaboration with CCrest Laboratories Inc. ("CCrest Laboratories" or "CCrest"), a Montreal-based cGMP pharmaceutical laboratory that holds a Controlled Drugs & Substances Dealer's License from Health Canada, has developed dehydrated, homogenized psilocybin microdosing capsules from its natural psilocybin truffles imported from our Netherlands farm. The capsules have passed the certificate of analysis testing and, based on stability testing, shelf life has been determined to be 4 months.

NUBU pharmaceuticals, the company's distribution partner in Australasia, has completed the rigorous application process with New Zealand's Ministry of Health to secure a 'License to Deal in Controlled Drugs', a 'License to Wholesale Medicines', and now a Medicinal Cannabis Supply License from the Medicinal Cannabis Agency. NUBU Pharmaceuticals currently has distribution deals with six companies: ECS Botanics, Sciva International s.r.o., InterCure Ltd. (dba Canndoc), MGC Pharmaceuticals Ltd., and Australian Natural Therapeutics Group Pty Ltd. (ANTG), to supply medicinal cannabis products, as well as Canopy Growth Corporation's Storz & Bickel GmbH for medical cannabis vaporizers.

PharmAla Biotech ("PharmAla") is assisting the company in navigating regulation and development of the Company's Psilocybin products towards being able to legally sell them to Clinical Trials, Special Access Program customers and/or other emerging markets. Under the terms of the contract, PharmAla's manufacturing experts have been retained by the Company to consult and provide their expertise to Red Light in an all-cash consulting contract for one year, with the goal of developing GMP and regulatory documentation of the Company's Psilocybin

capsule products. The agreement also includes the provision that, upon completion of the drug product to specification, PharmAla and the Company may enter into a sales agreement, where PharmAla would sell the products or provide them to its affiliates in global markets as the Company's exclusive sales agent.

United States

Wisdom Truffle:

The Wisdom project, led by Radix Motion Inc. ("Radix Motion"), which was intended to be a set of smart home figurines designed by Karim Rashid utilizing ideas from the mycelium network, has paused the development of future models and focused listing the Moon model, a meditation aid, on Amazon to increase sales.

With the Moon model design completed, and the initial manufacturing run of the first 100 units has been produced and delivered to Canada and the Netherlands. An additional production run of 400 units has also been completed through the manufacturer in China with shipment to be confirmed once the Amazon listing has been finalized.

MisterCap:

Post-launch of the MisterCap branded grow at home mushroom kit product line, the Company has revised its strategy to focus on growing retail distribution, as opposed to marketing online sales, in an effort to grow the brand organically and hit our target market. The Company is currently negotiating with a North American retailer which could see an initial delivery in the coming months.

RESULTS OF OPERATIONS

Revenue and Gross Profit

(Unaudited)	Three months ended		Nine months ended	
	Dec 31		Dec 31	
	2023	2022	2023	2022
Revenue	1,291,070	1,175,235	3,476,072	2,696,749
Cost of sales	744,671	588,081	1,961,908	1,532,742
Gross profit	546,399	587,154	1,514,164	1,164,007
<i>Gross profit as a % of sales</i>	42.3%	50.0%	43.6%	43.2%

Revenue for the three and nine months ended December 31, 2023 resulted in an increase of 9.9% and 28.9%, respectively, over the comparative periods in the prior year. The Company benefited from the increased sales related to the prior year's acquisitions of the two SmartShops and MiniChamp; an increase in SR Wholesale sales related to increased tourism in the Netherlands; an increase in AEM sales as production approached their expected capacity; and an increase in Happy Caps sales related to sales channel penetration into the grocery market.

Gross profit for the three and nine months ended December 31, 2023 resulted in a decrease of (6.9%) and an increase of 30.1%, respectively, over the comparative periods in the prior year. The decrease in the quarter is predominately the product mix within sales and the increase for the nine month period is as a result of the improved sales activity noted above and efficiencies gained through production improvements and product mix which have increased gross profit as a percentage of sales to 43.6% (2022 – 43.2%).

Revenue by Geographical Segments

(Unaudited)	Three months ended		Nine months ended	
	Dec 31		Dec 31	
	2023	2022	2023	2022
Netherlands	739,633	658,154	2,242,274	1,722,773
Canada	551,437	517,081	1,228,638	973,976
United States	-	-	5,160	-
	1,291,070	1,175,235	3,476,072	2,696,749

For the three and nine months ended December 31, 2023, revenue derived from the operations in the Netherlands predominately consisted of the Company's farms' production and sale of psilocybin truffles; SR Wholesale's sale and distribution of products to SmartShops within the Netherlands; the SmartShops in Oss and Utrecht; and the sale of kits from the MiniChamp mushroom home grow kit production facility. Revenue for the quarter also included sales from the Canadian operations of Happy Caps which produces and distributes grow at home mushroom kits for the North American market and AEM farm which produces and sells functional mushrooms within the North American wholesale market.

General and Administrative

The following table presents the components of general and administrative expenditures:

(Unaudited)	Three months ended		Nine months ended	
	Dec 31		Dec 31	
	2023	2022	2023	2022
Advertising and promotions	142,912	193,963	258,732	302,407
Amortization and depreciation	171,303	156,287	510,743	443,722
Consulting and management fees	204,340	248,867	620,142	789,418
Investor and public relations	4,774	9,496	17,584	35,596
Legal, audit and other professional fees	125,680	163,282	492,812	466,206
Office and general	604,076	447,939	1,283,788	935,310
Payroll	444,319	463,576	1,485,143	1,251,365
Regulatory	15,781	20,196	49,746	34,196
General and administrative	1,713,185	1,703,606	4,718,690	4,258,220

General and administrative expenses increased during the three and nine months ended December 31, 2023 by \$9,579 (or 0.6%) and \$460,470 (or 10.8%), respectively. For the nine month period, these costs have increased partially as a result of the prior year acquisitions of two SmartShops and MiniChamp plus the impact of general growth in operations. The increase in payroll is partially offset by the decrease in consulting and management fees as a number of consultants have been extended employment contracts.

Share Based Payments

Share based payments for the three and nine months ended December 31, 2023 includes the value of stock options (“Options”) and RSUs that vested during the period, and the value of shares issued to various consultants as compensation for services rendered.

Research

The costs included in research relate to the product design costs associated with the Company’s product line of Wisdom Truffle smart home figurines and research expenditures related to the psilocybin microdosing capsules being developed at the Company’s laboratory partner, CCrest Laboratories Inc.

Other Items

(Unaudited)	Three months ended		Nine months ended	
	Dec 31		Dec 31	
	2023	2022	2023	2022
Realized loss on sale of marketable securities	-	-	-	(19,364)
Change in fair value of marketable securities	4,159	(99,336)	(32,867)	(346,191)
Realized gain on sale of property, plant and equipment	-	-	13,138	-
Reversal of provision for sales tax receivable	-	205,636	-	205,636
Change in fair value of convertible debenture	-	(46,759)	-	(56,711)
Change in fair value of derivative liability	11,037	-	38,405	-
Change in fair value of call option	-	358	(28,110)	(1,760)
Change in fair value of contingent consideration	-	(158,345)	-	-
Foreign exchange (loss) gain	(2,719)	(4,579)	(746)	(9,183)
Interest income	135,689	54,725	399,931	106,836
Other Items	148,166	(48,300)	389,751	(120,737)

For the three and nine months ended December 31, 2023, the unrealized change in fair value of marketable securities amounted to a gain of \$4,159 and a loss of \$32,867, respectively, (2022 – a loss of \$99,336 and \$346,191, respectively), which is recorded in the condensed interim consolidated statements of loss and comprehensive loss.

Interest income for the three and nine months ended December 31, 2023 and 2022 reflects interest earned on surplus funds. The Company has invested excess cash in short term redeemable GICs with Canadian banks and is earning interest income in line with current market yields.

Net Loss

(Unaudited)	Three months ended		Nine months ended	
	Dec 31		Dec 31	
	2023	2022	2023	2022
Loss before taxes	(1,248,499)	(1,373,775)	(4,263,853)	(4,301,600)
Provision for income taxes	28,932	61,429	58,700	148,758
Net loss	(1,219,567)	(1,312,346)	(4,205,153)	(4,152,842)
Net loss attributable to:				
Shareholders of Red Light Holland Corp.	(1,193,397)	(1,305,436)	(4,136,373)	(4,072,769)
Non-controlling interests	(26,170)	(6,910)	(68,780)	(80,073)
Net loss	(1,219,567)	(1,312,346)	(4,205,153)	(4,152,842)
Loss per share (basic and diluted)	(0.00)	(0.00)	(0.01)	(0.01)
Weighted average Common Shares outstanding	394,404,102	378,439,289	394,175,587	376,812,501

The net loss for the three and nine months ended December 31, 2023 as compared to the prior year has been largely impacted by the aforementioned increase in general and administrative costs offset by improved non-operational results listed in “Other Items”. Net loss attributable to non-controlling interests is the results of operations, after tax, from Happy Caps and AEM that are attributable to our minority partners.

SUMMARY OF QUARTERLY RESULTS

\$ thousands, except per share amounts (Unaudited)	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022
Revenue	1,291	983	1,202	1,253	1,175	736	785	622
Gross profit	546	445	523	543	587	288	289	132
Gross margin %	42.3%	45.2%	43.5%	43.3%	50.0%	39.1%	36.8%	21.2%
General and administrative	1,713	1,450	1,555	1,738	1,703	1,306	1,249	1,770
Share based payments	156	155	912	47	87	91	338	485
Interest expense	72	60	47	37	9	6	4	2
Research	2	16	30	(39)	113	130	102	753
Loss before other items and taxes	(1,397)	(1,236)	(2,021)	(1,239)	(1,325)	(1,245)	(1,404)	(2,878)
Realized gain (loss) on sale of marketable securities	-	-	-	32	-	(20)	1	-
Provision for sales tax receivable	-	-	-	-	205	-	-	(433)
Change in fair value of marketable securities	4	(2)	(36)	(18)	(99)	(47)	(199)	683
Realized gain on sale of property and equip	-	-	13	-	-	-	-	-
Foreign exchange (loss) gain	(3)	(4)	6	(10)	(5)	(4)	(1)	(5)
Change in fair value of convertible debenture	-	(36)	36	-	(47)	(11)	1	117
Change in fair value of derivative liability	11	14	14	-	-	-	-	-
Change in fair value of call option	-	-	(28)	(81)	-	3	(6)	-
Change in fair value contingent consideration	-	-	-	-	(158)	(48)	-	-
Impairment of intangible assets	-	-	-	(444)	-	-	-	(5,937)
Interest income	136	137	128	102	55	34	18	16
Income (loss) before taxes	(1,249)	(1,127)	(1,888)	(1,659)	(1,374)	(1,338)	(1,590)	(8,437)
Provision for income taxes	29	19	11	11	62	33	55	247
Net income (loss)	(1,220)	(1,108)	(1,877)	(1,648)	(1,312)	(1,305)	(1,535)	(8,190)
Diluted earnings (loss) per share	(0.00)	(0.00)	(0.00)	(0.00)	(0.00)	(0.00)	(0.00)	(0.02)

The Company reported a consolidated net loss of \$1,219,567 (\$0.00 per share) for the quarter ended December 31, 2023 as compared to a consolidated net loss of \$1,312,346 (\$0.00 per share) in the quarter ended December 31, 2022.

Comparing the results for the current quarter over the prior year, the aforementioned increase in sales and gross profit was offset by increases in general and administrative expenditures.

STATEMENT OF FINANCIAL POSITION – SUMMARY

(Unaudited)	Dec 31 2023	Mar 31 2023
Cash and cash equivalents	15,418,931	18,486,644
Accounts receivable	529,504	518,146
Sales tax receivable	463,629	283,397
Income tax receivable	35,738	81,652
Marketable securities	12,631	45,498
Prepaid expenses and deposits	2,090,569	2,051,361
Inventory	943,375	741,249
Total Current Assets	19,494,377	22,207,947
Property, plant and equipment	5,106,542	4,806,140
Marketable securities – non-current	865,268	865,268
Right of use assets	439,776	581,932
Call option	-	28,110
Intangible assets	125,468	339,352
Goodwill	1,308,779	1,314,534
Total Assets	27,340,210	30,143,283
Accounts payable and accrued liabilities	1,554,139	1,292,333
Loans and advances	905,059	905,059
Convertible debenture	320,275	257,695
Derivative liability	9,971	48,376
Lease liability – current portion	139,509	179,819
Total Current Liabilities	2,928,953	2,683,282
Lease liability	324,827	422,618
Contingent consideration	38,077	188,077
Deferred tax liability	449,734	506,476
Total Liabilities	3,741,591	3,800,453
Total Shareholders' Equity	23,598,619	26,342,830
Total Liabilities and Shareholders' Equity	27,340,210	30,143,283

Red Light Holland's primary asset is cash and cash equivalents. The Company also holds investments in marketable securities. Inventory is primarily wholesale products in our warehouse facility in the Netherlands and also includes materials and finished goods production from our mushroom and truffle growing facilities in Canada and the Netherlands. Prepaid expenses include the deferred marketing charges related to the initial costs associated with the Mistercap's brand intellectual property agreement.

Property, plant and equipment includes the mushroom production facility in New Brunswick, valued at \$2.5 million, and the farmland in Ontario acquired for \$1.9 million.

Accounts payable and accrued liabilities have increased slightly over the comparative period as a result of the increase in trade payables.

LIQUIDITY

We assess liquidity in terms of our ability to generate sufficient cash flow, along with other sources of liquidity including cash and the ability to borrow through leases to fund our operations and growth in operations.

Summary of Cash Inflows (Outflows)

(Unaudited)	Nine months ended Dec 31	
	2023	2022
Net loss	(4,205,153)	(4,152,842)
Non-cash items and changes in working capital	1,738,373	826,913
Cash flows from operating activities	(2,466,780)	(3,325,929)
Cash flows from investing activities	(446,762)	(3,057,843)
Cash flows from financing activities	(142,157)	(98,920)
Change in foreign currency rates on cash	(12,014)	84,748
Change in cash	(3,067,713)	(6,397,944)
Cash, beginning of period	18,486,644	26,093,738
Cash, end of period	15,418,931	19,695,794

Cash Flows From Operating Activities

The cash used in operating activities decreased over the prior year predominately as a result of improved operational results, adjusted for non-cash items, more than offsetting further investments in working capital related predominately to increases in inventory and sales tax receivables.

Cash Flows From Investing Activities

The cash used in investing activities in the current year is comprised of capital expenditures of \$466,762 offset by proceeds from the sale of property, plant and equipment of \$19,593.

In the prior period, proceeds from the sale of marketable securities was \$65,339 offset by payments related to the acquisition of subsidiaries in the amount of \$957,974, acquisition earn-out payments of \$100,000 and capital expenditures of \$2,065,208.

Cash Flows From Financing Activities

Cash used in financing activities in the current year relates to proceeds from the exercise of warrants and options in the amounts of \$12,000 and \$90,000, respectively, offset by share repurchases of \$77,510 and lease payments in the amount of \$166,647. In the prior year, the cash outflows related to the value of the lease payments in the amount of \$98,920.

Share Capital – Outstanding Shares

Changes in the number of issued and outstanding shares during the nine months ended December 31, 2023 and the year ended March 31, 2023 were as follows:

	Nine months ended Dec 31 2023	Year ended Mar 31 2023
Balance, opening	387,892,187	358,165,282
Shares issued per consulting and service agreements	-	13,625,731
Exercise of warrants	200,000	-
Exercise of Options	1,500,000	833,333
Exercise of RSUs	3,159,305	5,604,559
Shares issued for contingent considerations	1,543,208	957,853
Shares issued on conversion of debentures	952,380	-
Shares purchased through normal course issuer bid	(1,262,000)	-
Shares issued on acquisitions	-	2,405,429
Shares issued for legal retainer	-	6,300,000
Balance, closing	393,985,080	387,892,187

The following is selected share capital information related to the Company as at December 31, 2023 and March 31, 2023:

	Dec 31, 2023	Mar 31, 2023
Common Shares issued and outstanding	393,985,080	387,892,187
Options outstanding	27,101,667	15,766,667
Broker warrants and share purchase warrants outstanding	76,958,736	78,020,641
RSUs outstanding	3,866,667	300,516
Fully diluted shares outstanding	501,912,150	481,980,011

On July 13, 2023, the Company initiated the NCIB. During the period ended December 31, 2023, the Company repurchased 1,262,000 Common Shares under the NCIB at a total purchase value of \$77,510.

CAPITAL RESOURCES

The capital managed by the Company includes the components of shareholders' equity as described in the Interim Financial Statements for the period ended December 31, 2023. The Company is not subject to externally imposed capital requirements.

The Company's objectives of capital management are to create long-term value and economic returns for its shareholders. It does this by seeking to maximize its resources to fund the growth and development of its business, and to support the working capital required to maintain its ability to continue as a going concern. The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of its assets by seeking

to limit shareholder dilution and optimize its cost of capital while maintaining an acceptable level of risk. In order to maintain or adjust its capital structure, the Company considers all sources of financing reasonably available to it, including but not limited to the issuance of new capital and the issuance of new debt.

The Company's ability to access both public and private capital is dependent upon, among other things, general market conditions and the capital markets generally, market perceptions about the Company and its business operations, and the trading prices of the Company's securities from time to time. When additional capital is required, the Company intends to raise funds through the issuance of equity or debt securities. Other possible sources include the exercise of Options and warrants of the Company. There can be no assurance that additional funds can be raised upon terms acceptable to the Company, or at all, as funding for early-stage companies remains challenging generally. Given the nature of the Company's business as of the date of this MD&A, and in particular, the fact that a significant portion of its operations are undertaken exclusively within a foreign jurisdiction, the Company may face difficulty in accessing traditional sources of financing, notwithstanding that its business operations are conducted in a regulatory environment within which the Company's activities are neither illegal nor subject to conflicting laws.

OFF BALANCE SHEET TRANSACTIONS

The Company does not have any financial arrangements that are excluded from the Interim Financial Statements as of December 31, 2023, nor are any such arrangements outstanding as of the date of this MD&A.

RELATED PARTY TRANSACTIONS

During the three and nine months ended December 31, 2023 and 2022, compensation, paid or payable, to persons and corporations in charge of the planning, direction and control of the Company, including executive and non-executive directors, is as follows:

(Unaudited)	Three months ended		Nine months ended	
	Dec 31		Dec 31	
	2023	2022	2023	2022
Salary	185,000	167,500	716,250	419,167
Consulting fees	172,957	83,300	317,122	327,394
Car allowances	4,800	3,300	11,400	9,900
Other	9,000	6,600	26,200	260,550
	371,757	260,700	1,070,972	1,017,011

During the prior nine months ended December 31, 2022, payments relating to the tax impact of certain executive management personnel electing to receive vested RSUs on a net of tax basis, resulting in the expense and remittance of related tax withholdings in the amount of \$240,750, were included in general and administrative expenditures in the consolidated statement of loss and comprehensive loss and recorded in other in the above table.

As at December 31, 2023, \$64,211 (March 31, 2023 - \$17,937) was due to related parties and included in accounts payable and accrued liabilities.

Equity Transactions

Shares issued during the nine months ended December 31, 2023 and 2022 to persons and corporations in charge of the planning, direction and control of the Company, including executive and non-executive directors, is as follows:

- On April 24, 2023, the Company issued 4,950,000 RSUs to Directors of the Company.
- The Company issued the following Options to Directors and Officers of the Company:

Option Grant Date	Options Granted #	Option Value \$
April 24, 2023	13,550,000	1,025,083
October 30, 2023	600,000	25,225

SUBSEQUENT EVENT(S)

Other than as disclosed herein, there are no material subsequent events from January 1, 2024 to the reporting date of this MD&A.

On January 15, 2024 the Company announced that it has received the building permit for AEM Farms' 80,000 square foot mushroom farm.

On January 23, 2024 the Company announced that cGMP pharmaceutical company, CCrest Laboratories, has completed the Product Specification report for its homogenized psilocybin microdosing capsules. The report encompasses and confirms detailed testing methodologies and an established shelf life based on documented stability testing results.

On January 25, 2024 the Company announced strategic changes and the launch of SR Wholesale North America, a fresh mushroom sales division. The strategic move is aimed at expanding the Company's product offering and market presence by focusing on the sale of fresh mushrooms sourced from its AEM partners, including Holburne and F&R Mushrooms.

On February 9, 2024 the Company announced a collaboration with PharmAla on medical psilocybin development. The collaboration will focus on the development of a clinical-grade psilocybin drug product extracted from the Company's naturally occurring psilocybin truffles.

On February 27, 2024 the Company announced the receipt of a Health Canada Import Permit allowing the shipment of 5kg of the Company's natural psilocybin truffles grown at the Company's farm in the Netherlands for delivery to CCrest Laboratories Inc., a Montreal based cGMP pharmaceutical laboratory. This is the fifth permit relating to the collaboration between the Company and CCrest and represents the largest shipment to date. The purpose of the import is to further the Company's research program with consultation from PharmAla Biotech with the goal of achieving all regulatory requirements to sell natural psilocybin products to clinical trials.

CRITICAL ACCOUNTING ESTIMATES AND CHANGES TO ACCOUNTING POLICIES

Critical Accounting Estimates

All significant critical accounting estimates are fully disclosed in Note 3 of the Annual Financial Statements.

Future Accounting Standards

Classification of Liabilities as Current or Non-Current (Amendments to IAS 1):

The IASB has published Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) which clarifies the guidance on whether a liability should be classified as either current or non-current. The amendments:

- clarify that the classification of liabilities as current or non-current should only be based on rights that are in place at the end of the reporting period;
- clarify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability; and
- make clear that settlement includes transfers to the counterparty of cash, equity instruments, other assets or services that result in extinguishment of the liability.

This amendment is effective for annual periods beginning on or after January 1, 2023. Earlier application is permitted. The extent of the impact of adoption of this amendment has not yet been determined.

Presentation of Financial Statements (Amendments to IAS 1):

The IASB has published Disclosure of Accounting Policies (Amendments to IAS 1) which clarifies the guidance on applying the concept of materiality. These amendments help companies provide useful accounting policy disclosures, and they include:

- requiring companies to disclose their material accounting policies instead of their significant accounting policies;
- clarifying that accounting policies related to immaterial transactions, other events or conditions are themselves immaterial and do not need to be disclosed; and
- clarifying that not all accounting policies that relate to material transactions, other events or conditions are themselves material.

This amendment is effective for annual periods beginning on or after January 1, 2023. Earlier application is permitted. The extent of the impact of adoption of this amendment has not yet been determined.

COMMITMENTS, PROVISIONS AND CONTINGENCIES

The Company is party to legal proceedings and other claims in the ordinary course of its operations. Litigation and other claims are subject to many uncertainties and the outcome of individual matters is not predictable. Where management can estimate that there is a loss probable, a provision has been recorded in its financial statements, where proceedings are at a premature stage or the ultimate outcome is not determinable, then no provision is recorded. It is possible that the final resolution of these matters may require the Company to make expenditures over an extended period of time and in a range of amounts that cannot be reasonably estimated and may differ significantly from any amounts recorded in these consolidated financial statements. Should the Company be unsuccessful in its defense or settlement of one or more of these legal actions, there could be a materially adverse effect on the Company's financial position, future expectations, and cash flows.

DISCLOSURE CONTROLS AND INTERNAL CONTROLS OVER FINANCIAL REPORTING

Disclosure controls and procedures

Disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by the Company in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in the securities legislation and include controls and procedures designed to ensure that information required to be disclosed by the Company in its annual filings, interim filings or other reports filed or submitted under securities legislation is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Management, including the Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of the Company's disclosure controls and procedures. As of December 31, 2023, the Chief Executive Officer and Chief Financial Officer have each concluded that the Company's disclosure controls and procedures, as defined in NI 52-109 - *Certification of Disclosure in Issuer's Annual and Interim Filings*, are effective to achieve the purpose for which they have been designed.

Internal controls over financial reporting

Internal controls over financial reporting are designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with IFRS. Management is also responsible for the design of the Company's internal control over financial reporting in order to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS.

The Company's internal controls over financial reporting include policies and procedures that pertain to the maintenance of records that, in reasonable detail accurately and fairly reflect the

transactions and disposition of assets; provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements in accordance with IFRS and that receipts and expenditures are being made only in accordance with authorization of management and directors of the Company; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on the financial statements.

Management, including the Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of the Company's internal controls over financial reporting. As of December 31, 2023, the Chief Executive Officer and Chief Financial Officer have each concluded that the Company's internal controls over financial reporting, as defined in NI 52-109 - *Certification of Disclosure in Issuer's Annual and Interim Filings*, are effective to achieve the purpose for which they have been designed.

Because of their inherent limitations, internal controls over financial reporting can provide only reasonable assurance and may not prevent or detect misstatements. Furthermore, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

RISK MANAGEMENT

The following is a description and analysis of the risks associated with financial instruments that may affect the Company:

Fair Value of Financial Assets and Financial Liabilities

Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest rate, currency or credit risks arising from its financial instruments. The fair values of the Company's financial assets and financial liabilities approximate their carrying amounts due to their imminent or short-term maturity.

Other Price Risk

The Company is exposed to price risk through its investments in publicly traded and private marketable securities. A 10% change in the fair value of these securities would change the Company's net loss by \$87,790.

Interest Rate Risk

The Company's current policy is to invest excess cash in investment-grade short-term deposit certificates issued by its banking institutions. The Company periodically monitors the investments it makes and is satisfied with the credit ratings of its banks. The fair value measurement of convertible debentures is impacted by market interest rates. As a result, the

Company is exposed to interest rate movements, which impact the fair value of the Company's outstanding promissory note.

Foreign Exchange Risk

Foreign exchange risk is the risk that the market value of financial instruments and the associated revenues will fluctuate due to changes in exchange rates. The Company does not use derivatives to modify the foreign exchange risk. The Company holds minimal financial instruments in foreign currencies.

The Company's functional and reporting currency is the Canadian dollar. Foreign exchange risk arises from transactions denominated in currencies other than the Canadian dollar. The Company's primary foreign exchange exposure is the Euro, being the local currency in the Netherlands where the Company's subsidiaries RLH Netherlands BV, RLH Farms BV, SR Wholesale BV, MiniChamp BV, Wellness World Oss BV and Wellness World Utrecht BV operate.

The Company is exposed to currency risk through the assets and liabilities denominated in currencies other than the Canadian dollar. As at December 31, 2023, the Company has \$2,451,252 of net assets and liabilities that are denominated in currencies other than the Canadian dollar. A 10% change in the value of net assets and liabilities that are denominated in currencies other than the Canadian dollar as a result in changes in foreign exchange rates would change the Company's net loss by \$245,125.

Liquidity Risk

Liquidity risk is the risk that results from the Company's potential inability to meet its financial obligations as they come due. The Company manages liquidity risk by reviewing the amount of cash available to ensure that it can meet its current obligations.

	Payments due by period			
	Total	< 1 Year	1-3 Years	4-5 Years
Accounts payable and accrued liabilities	1,554,139	1,554,139	-	-
Loans and advances	905,059	905,059	-	-
Lease liability	531,989	170,795	272,397	88,797
Convertible debenture	391,173	391,173	-	-
	3,382,360	3,021,166	272,397	88,797

Credit Risk

Credit risk is the risk that the counterparty to a financial instrument will fail to discharge an obligation or commitment that it has entered into with the Company. Financial instruments which

potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents, marketable securities, accounts receivable, and sales tax receivable.

The Company has trade accounts receivable from customers, and sales tax receivable. The Company's credit risk arises from the possibility that a counterpart which owes the Company money is unable or unwilling to meet its obligations in accordance with the terms and conditions in the contracts with the Company, which would result in a financial loss to the Company. These specific customers may be affected by economic factors and government and legal factors which may impact accounts receivable. Credit risk for accounts receivable is assessed on a case-by-case basis and a provision is recorded where required. As of December 31, 2023, the Company estimated its expected credit losses to be \$53,095 (March 31, 2023 - \$49,123).

The Company's credit risk is primarily attributable to accounts receivable and sales tax receivable. The Company has no significant concentration of credit risk arising from operations. Cash and marketable securities are held with reputable financial institutions and cash held with a law firm, from which management believes the risk of loss to be remote.

RISK FACTORS

Due to the nature of the Company's business, its limited operating history, and its stage of development, an investment in the securities of the Company is highly speculative and involves significant risks and uncertainties. As the Company continues to develop its business, the Company will face numerous challenges, and additional risks and uncertainties not presently known to the Company, or which the Company believes to be immaterial. In the event that such risks and uncertainties materialize, the Company's business, financial condition, and results of operations could be materially adversely affected, and shareholders of the Company could lose all or part of their investment in the Company. Such risks and uncertainties could also cause actual events to differ materially from those described in forward looking statements relating to the Company described in this MD&A and in certain documents incorporated by reference into this MD&A.

The following section summarizes certain of the risks and uncertainties relating to the business of the Company as of the date of this MD&A. The summary of such risks and uncertainties is not intended to be exhaustive, and such risks are in addition to the usual risks associated with investment in a business. Investors should carefully consider the following risks and uncertainties as well as the risk factors set out in the Company's listing statement dated May 25, 2020 and annual information form dated January 11, 2021, which can be accessed under the Company's SEDAR+ profile.

Introduction of, or Changes in, Laws, Regulations and Guidelines

Although the cultivation, production and distribution of fresh, unprocessed truffles within the Netherlands is not, as of the date of this MD&A, subject to regulation as, for example, the cannabis industries in Canada and the United States, the Company's operations in the Netherlands remain subject to compliance with the *Opium Act* (the Netherlands), as well as other laws, regulations, and guidelines in effect from time to time enacted by applicable governmental authorities and

financial institutions. Although the Company is, to its knowledge, in compliance with all applicable laws and regulations (and intends to continue to comply), there can be no guarantee that new laws, regulations, and guidelines will not be enacted, or that existing or future laws and regulations will not be changed. Any introduction of new (or changes to existing) laws, regulations, and guidelines, or other unanticipated events could require extensive changes to the Company's operations, increase compliance costs, and give rise to material liabilities, which could have a material adverse effect on the business, financial condition and operating results of the Company.

No Assurance of Commercial Success or Profitability

The successful commercialization of the Company's product offering including grow at home mushroom kits, functional mushrooms and its brand of truffles sold in the Netherlands will depend on many factors, including: (i) the Company's ability to establish and maintain new and existing working partnerships with industry partners in order to source, distribute, and market its product offerings, (ii) the Company's ability to supply a sufficient amount of its product offerings to meet market demand, and (iii) the number of competitors from time to time competing with the Company. As the Company continues to grow and expand its operations, there is a risk that the markets in which it operates may become increasingly competitive in all its phases, and in particular as a result of the possibility that new entrants could attempt to mirror the Company's business model and establish operations. There can be no assurance that the Company or its industry partners will be successful in their respective efforts to develop and implement, or assist the Company in developing and implementing, a commercialization strategy for the Company's product offerings. Further, there can be no assurance that consumer demand for the Company's product offerings will be as anticipated, or that the Company will become profitable.

Limited Operating History in Truffles Industry

The Company began operations in the Netherlands in fiscal Q2 2020 and has a limited operating history within the truffles industry. As such, the Company will be subject to all of the business risks and uncertainties associated with any early staged enterprise, including the risks that it will be unable to: (i) successfully cultivate, produce, distribute truffles, (ii) establish a market for its products, (iii) achieve its growth objectives and targets, and/or (iv) successfully assess and meet consumer demand and become profitable. The Company's future growth will depend substantially on its ability to address these and the other risks described in this section of this MD&A, and any failure to successfully address such risks could have a material adverse effect on the business, financial condition and operating results of the Company.

Difficulty to Forecast

The Company must rely largely on its own market research to forecast sales as detailed forecasts are not generally obtainable from other sources at this early stage of the truffles industry in the Netherlands. A failure in the demand for the Company's brand of truffles and future product offerings to materialize as a result of competition, technological change or other factors could have a material adverse effect on the business, financial condition and operating results of the Company.

Unfavourable Publicity or Consumer Perception

The Company's success within the truffles industry may be significantly influenced by consumer perception of truffles generally, or the Company's brand of truffles and future products, any of

which can be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of truffles and products produced or manufactured using truffles. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favourable to the truffles industry or any particular product offering of the Company, or consistent with earlier publicity. Any adverse scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity, whether or not accurate or with merit, could have a material adverse effect on the business, financial condition, ability to finance and the operating results of the Company.

Reliance on Key Personnel

The Company's success has depended, and will continue to depend, on the efforts and talents of its executives and employees, including its Chief Executive Officer, and its ability to attract, develop, motivate and retain highly qualified and skilled employees, staff and consultants. Qualified individuals are in high demand, and the Company may incur significant costs to attract and retain them. In addition, the loss of any of the Company's senior management or key employees could materially adversely affect its ability to execute its business plan and strategy, and it may not be able to find adequate replacements on a timely basis, or at all. The loss of any such key persons or the inability to find and retain new key persons could have a material adverse effect on the business, financial condition and operating results of the Company.

Liability, Enforcement Complaints, etc.

As a company engaged in the truffles industry within the Netherlands, the Company and/or its subsidiaries may from time to time become subject to litigation, formal or informal complaints, enforcement actions, and inquiries, including by one or more federal or local governmental authorities in the Netherlands. Any such litigation, complaints, and/or enforcement actions involving the Company and/or its subsidiaries could consume a considerable amount of financial and other corporate resources and the time of the Company's management and could have a material adverse effect on the business, financial condition and operating results of the Company.

Reliance on Operations in Foreign Jurisdictions

As of the date of this MD&A, the Company's psilocybin truffle operations are conducted primarily within the Netherlands. As such, the Company's psilocybin truffle operations at various times may be exposed to political, economic and other risks and uncertainties associated with operating in a foreign jurisdiction. These risks and uncertainties include, but are not limited to: (i) renegotiation, nullification, termination or rescission of concessions, licenses, permits and contracts, from time to time held by the Company or to which the Company a party, (ii) changing political conditions, (iii) currency exchange rate fluctuations, (iv) taxation policies, and (v) changing government policies and legislation. The Company's operations within the Netherlands may also be affected in varying degrees by changes to laws, regulations, access to banking and financial institutions, and guidelines applicable to foreign entities with respect to, but not limited to, the production of truffles, price controls, currency remittance, income taxes (including VAT), foreign investment, environmental legislation, and use of real property. Any change in such or similar laws, regulations, and guidelines, or shifts in political attitude, could have an adverse effect on the Company's future cash flows, earnings, results of operations and financial condition. The

Company cannot accurately predict the full impact of any such occurrence on the Company's operations and profitability. Finally, the Company may be subject to the exclusive jurisdiction of courts of the Netherlands in the event of any dispute arising from the Company's operations in the Netherlands.

Product Liability

As a cultivator, producer and distributor of products intended be ingested by humans, the Company faces an inherent risk of exposure to product liability claims, regulatory actions and litigation if the Company's product offerings are alleged to have caused loss or injury. In addition, the sale of the Company's product offerings involves the risk of injury or loss to consumers due to tampering by unauthorized third parties, product contamination and unauthorized use by consumers or other third parties. Previously unknown adverse reactions resulting from human consumption of the Company's truffles alone or in combination with other medications or substances could occur. The Company may be subject to various product liability claims, including that the Company's product offerings caused death, injury, illness, or other loss. A product liability claim or regulatory action against the Company could result in increased costs, adversely affect the Company's reputation with consumers, and could have a material adverse effect on the business, financial condition and operating results of the Company.

Product Viability of Truffles

In general, truffles have minimal long-term data with respect to efficacy, unknown side effects and/or interaction with individual human biochemistry or other supplements or medications. As a result, the Company's brand of truffles could have certain side effects if not used as directed or if taken by an end user that has certain known or unknown medical conditions. If the Company's brand of truffles and future product offerings are not perceived to have the effects intended by the end user, the Company's business and its reputation may suffer, any of which could have a material adverse effect on the business, financial condition and operating results of the Company.

Product Recalls

The Company's brand of truffles, functional mushrooms, grow at home mushroom kits and future product offerings may be subject to the recall or return for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labeling disclosure. If any of the Company's product offerings are recalled due to an alleged product defect or for any other reason, the Company could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. The Company may lose a significant number of sales transactions and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention and otherwise distract from day-to-day operations. As such, any product recall could have a material adverse effect on the business, financial condition and operating results of the Company.

Competitive Conditions

The Netherlands is an ideal location to establish and operate a vertically integrated truffles company, primarily due to its favourable regulatory regime, and access to a strong and established consumer base for the sale of truffles. The truffles industry within the Netherlands is an established

industry that is highly competitive. The market for access to truffles in the Netherlands has created a competitive environment for truffles producers as well as for SmartShop operators. The Company faces direct competition to attract and retain end-users and competes with other industry participants that may have greater financial resources and longer operating histories. The chief competitors of the Company's product offerings are expected to be existing producers as well as SmartShop operators. Although reliable data is limited, the Company believes that, as of the date of this MD&A, there are at least two (2) major producers of truffles within the Netherlands, and more than one hundred (100) SmartShop operators that offer truffles for sale. To remain competitive, the Company will require a continued high level of investment in acquisitions and investments, research and development, and marketing. The Company may not have sufficient resources to maintain such activities on a competitive basis which could have a material adverse effect on the business, financial condition and operating results of the Company.

Liquidity and Future Financing

Despite having operational farms in New Brunswick, Canada and Horst, The Netherlands, the Company has several product lines in their respective early stages of development and has not yet generated positive cashflow and will likely operate at a loss until such time as its business becomes established. Although the Company has, as of the date of this MD&A, sufficient capital to fund its ongoing business development and future growth and expansion plans for the foreseeable future, the Company may in the future require additional financing in order to fund such purposes. Furthermore, financial institutions may limit or avoid relationships, financing and the ability to transact to send or receive funds from entities that produce and/or sell psilocybin and psychedelic products due to their classification as narcotic substances. This may affect the Company's ability to transact business in the future. The Company's ability to secure any such required financing will depend, in part, upon investor perception of the Company's ability to build and maintain a successful business, as well as other factors beyond the Company's control. There can be no assurance that the Company will be able to successfully obtain additional financing, or that future financing will occur on terms satisfactory to the Company and/or its shareholders. If adequate funds are not available to the Company, or are not available on acceptable terms, the Company may be required to scale back its business plan or cease operating. Future financing conducted by issuing securities of the Company may result in shareholders suffering additional dilution.

Dependence on Third Parties

The Company has established relationships with various industry partners in the truffles industry in order to begin operations, develop its brand and product recognition, and generate revenue within the Netherlands. As of the date of this MD&A, the Company produces its brand of truffles and operates SR Wholesale as the primary sales channel of psilocybin product distribution and it now also operates two SmartShop locations within the Netherlands. Furthermore, it has established working relationships with industry partners in the truffles industry within the Netherlands, and to date, the Company's relationships have been a significant contributor to its ability to introduce its brand of truffles within the Netherlands. In particular, as of the date of this MD&A, the Company's brand of truffles is sold within retail establishments operated by industry partners which may be considered competitors of the Company within the truffles industry in the Netherlands, with certain of such industry partners having both their own dedicated SmartShops and cultivation and production facilities. In the event that one or more of the Company's industry partners were to

cease distributing the Company's brand of truffles through their own dedicated SmartShops, any such occurrence could have an adverse effect on the business, financial condition and operating results of the Company.

There can be no assurance that the Company will be able sustain its existing relationships with industry partners or establish and maintain new relationships with industry partners necessary to meet its ongoing business needs. Further, there can be no assurance that industry partners with which the Company has established relationships with will continue to meet the Company's business needs from time to time, on a timely basis, or at all.

From time to time, the Company may enter into strategic alliances with third parties that the Company believes will complement or augment its business or will have a beneficial impact on the Company. Strategic alliances with third parties could present unforeseen integration obstacles or costs, may not enhance the Company's business, and may involve risks that could adversely affect the Company, including the risk that significant amounts of management's time may be diverted from operations in order to pursue and complete such transactions or maintain such strategic alliances. Future strategic alliances could result in the Company incurring additional debt, costs and contingent liabilities, and there can be no assurance that future strategic alliances will achieve, or that the Company's existing strategic alliances will continue to achieve, the expected benefits to its business or that the Company will be able to consummate future strategic alliances on satisfactory terms, or at all. Any of the foregoing could have a material adverse effect on the business, financial condition and operating results of the Company.

Reliance on Informal Arrangements in the Truffle Market

As of the date of this MD&A, the Company has not entered into any binding written agreements with any of its existing industry partners. Instead, the Company's present business relationships with its current industry partners are based on informal arrangements of a nature customarily entered into by participants in the truffles industry within the Netherlands. As a result, in contrast to companies operating in other industries which may have written agreements with their respective industry partners, the Company is subject to the increased and unique risk that its existing arrangements with its industry partners may be terminated. Any such termination could have an adverse effect on the business, financial condition and operating results of the Company.

Cash Flow from Operations

To the extent that the Company has negative cash flow in any future period, certain of the net proceeds from future offerings may be used to fund such negative cash flow from operating activities. If the Company experiences future negative cash flow, the Company may also be required to raise additional funds through the issuance of equity or debt securities. There can be no assurance that the Company will be able to generate positive cash flow from its operations, that additional capital or other types of financing will be available when needed, or that these financings will be on terms favourable to the Company. In addition, the Company expects to achieve positive cash flow from operating activities in future periods. However, this is based on certain assumptions and subject to significant risks.

Regulatory Compliance Risks

Achievement of the Company's business objectives is subject to compliance with regulatory requirements enacted and enforced by governmental entities and obtaining and maintaining all required regulatory approvals. The Company may incur costs and obligations related to regulatory compliance. Failure to comply with applicable laws, regulations and permitting, license or approval requirements may result in enforcement actions hereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. The Company may be required to compensate those suffering loss or damage by reason of its operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations.

The Company cannot predict the timeline required to secure all appropriate regulatory approvals or licenses for its businesses or the extent of testing and documentation that may be required by governmental entities. Any delays in obtaining, or failing to obtain, required regulatory approvals or licenses may significantly delay or impact the research and development activities and could have a material adverse effect on the business, financial condition and operating results of the Company. In addition, changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to the Company's operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, financial condition and operating results of the Company.

The impact of the various legislative regimes, on the Company's business plans and operations is uncertain. There is no guarantee that the applicable legislation regulating its business activities will create or allow for the growth opportunities the Company currently anticipates.

Due to the nature of the Company's operations, various legal and tax matters may be outstanding from time to time. If the Company is unable to resolve any of these matters favorably, it could have a material adverse effect on the business, financial condition and operating results of the Company.

Public Company Consequences

The Company's status as a reporting issuer may increase price volatility due to various factors, including the ability to buy or sell its Common Shares, different market conditions in different capital markets and different trading volumes. In addition, low trading volume may increase the price volatility of the Common Shares. The increased price volatility could have a material adverse effect on the business, financial condition and operating results of the Company.

Fraudulent or Illegal Activity

The Company is exposed to the risk that its employees, independent contractors, consultants, service providers and licensors may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional undertakings of unauthorized activities, or reckless or negligent undertakings of authorized activities, in each case on the Company's behalf or in their services that violate (a) various applicable laws, including healthcare laws, (b) applicable laws that require the true, complete and accurate reporting of financial information or data, or (c) the terms

of the Company's agreements with third parties. Such misconduct could expose the Company to, among other things, class actions and other litigation, increased regulatory inspections and related sanctions, and lost sales and revenue or reputational damage.

The Company cannot always identify and prevent misconduct by its employees and other third parties, including third party service providers, and the precautions taken by the Company to detect and prevent this activity may not be effective in controlling unknown, unanticipated or unmanaged risks or losses or in protecting it from governmental investigations or other actions or lawsuits stemming from such misconduct. If any such actions are instituted against the Company, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on its business, including the imposition of civil, criminal or administrative penalties, damages, monetary fines and contractual damages, reputational harm, diminished profits and future earnings or curtailment of its operations.

General Economic Risks

The operations of the Company could be affected by the economic context should interest rates, inflation or the unemployment level reach levels that influence consumer trends and spending and, consequently, impact the sales and profitability of the Company. Investors should further consider, among other factors, the prospects for success, of the Company, in light of the risks and uncertainties encountered by companies that, like the Company, are in their early stages. The Company may not be able to effectively or successfully address such risks and uncertainties or successfully implement operating strategies to mitigate the impact of such risks and uncertainties. In the event that the Company fails to do so, such failure could have a material adverse effect on the business, financial condition and operating results of the Company.

Loss of Entire Investment

An investment in the Common Shares is speculative and may result in the loss of an investor's entire investment. Only potential investors who are experienced in high-risk investments and who can afford to lose their entire investment should consider an investment in the Company.

There can be no assurance regarding the amount of income to be generated by the Company. Common Shares are equity securities of the Company and are not fixed income securities. Unlike fixed income securities, there is no obligation of the Company to distribute to shareholders a fixed amount or any amount at all, or to return the initial purchase price of the Common Shares on any date in the future. The market value of the Common Shares may deteriorate if the Company is unable to generate sufficient positive returns, and that deterioration may be significant.

Management of Growth

The Company may experience a period of significant growth that will place a strain upon its management systems and resources. Its future will depend in part on the ability of its officers and other key employees to implement and improve financial and management controls, reporting systems and procedures on a timely basis and to expand, train, motivate and manage the workforce. The Company's current and planned personnel, systems, procedures and controls may be inadequate to support its future operations.

Conflicts of Interest

Certain of the Company's directors and officers may be involved in other business ventures through their direct and indirect participation in corporations, partnerships, joint ventures, etc. that may become potential competitors of the technologies, products and services the Company intends to provide. Situations may arise in connection with potential acquisitions or opportunities where the other interests of these directors' and officers' conflict with or diverge from the Company's interests. In accordance with applicable corporate law, directors who have a material interest in or who is a party to a material contract or a proposed material contract with the Company are required, subject to certain exceptions, to disclose that interest and generally abstain from voting on any resolution to approve the contract. In addition, the directors and officers are required to act honestly and in good faith with a view to the Company's best interests. However, in conflict-of-interest situations, the Company's directors and officers may owe the same duty to another company and will need to balance their competing interests with their duties to the Company. Circumstances (including with respect to future corporate opportunities) may arise that may be resolved in a manner that is unfavorable to the Company.

COVID-19 Pandemic

The Company's business could be adversely affected by the effects of the outbreak of novel coronavirus ("COVID-19"). To the date of this MD&A, the spread of COVID-19 has severely impacted many local economies around the globe. Measures taken to contain the spread of the virus, including travel bans, quarantines, social distancing, and closures of non-essential services have triggered significant disruptions to businesses worldwide, resulting in an economic slowdown. Global stock markets have also experienced great volatility and a significant weakening. Governments and central banks have responded with monetary and fiscal interventions to stabilize economic conditions. The duration and impact of the COVID-19 pandemic, as well as the effectiveness of government and central bank responses, remains unclear at this time. It is not possible to reliably estimate the duration and severity of these consequences, as well as their impact on the financial position and results of the Company for future periods. Since the initial outset of the pandemic, COVID-19 has not had a direct, material impact on the Company's operations and financial performance.

CAUTION REGARDING FORWARD LOOKING STATEMENTS

This MD&A contains FLS within the meaning of applicable securities legislation which involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or industry results, to be materially different from any future results, events, expectations, performance or achievements expressed or implied by such FLS. All statements, other than statements of historical fact, included herein may be FLS. FLS typically contains words or phrases such as "may", "outlook", "objective", "intend", "estimate", "anticipate", "should", "could", "would", "will", "expect", "believe", "plan", "predict" and other similar terminology suggesting future outcomes or events. FLS involves numerous assumptions and should not be read as guarantees of future performance or results. Such statements will not necessarily be accurate indications of whether or not such future performance or results will be achieved. Readers of this MD&A should not unduly rely on FLS as a number of factors,

many of which are beyond the control of the Company, could cause actual performance or results to differ materially from the performance or results discussed in the FLS.

Forward looking statements included throughout this MD&A include, but are not limited to, statements pertaining to the following:

- the Company's performance, business objectives and milestones and the anticipated timing and effects of, and costs in connection with, the execution or achievement of such objectives and milestones (including, without limitation proposed acquisitions, the launch, team, vision, supply, production and promotion of Mistercap's and its products, the launch and production of Wisdom Truffle and Moon units, the development and roll out of the Wellness World brand), the development and staffing of the Mushroom Facilities, and plans and developments under the distribution agreement with NUBU Pharmaceuticals);
- the Company's future growth prospects and intentions to pursue one or more viable business opportunities;
- the Company's proposed plans to execute on its business plan and obtain, maintain, and renew or extend, applicable licenses and authorizations, including the timing and impact of the receipt thereof;
- the development of the Company's business and future activities following the date of this MD&A;
- expectations relating to market size and anticipated growth in the jurisdictions within which the Company may from time to time operate or contemplate future operations;
- expectations with respect to economic, business, regulatory and/or competitive factors related to the Company and the industries within which it operates generally;
- the Company's strategic investments and capital expenditures, and related benefits;
- the Company's plans for growing its online retail and brick-and-mortar stores (including its SmartShops);
- the Company's plans to harvest, package, distribute, expand and increase sales of its products (including, without limitation, under its brands iMicrodose, Maka, Happy Caps and Mistercap's), leading to the Company's increased revenue and brand exposure;
- the market for the Company's current and proposed product offerings, as well as its ability to market and brand its products, the proposed mediums of distribution, and the timelines thereof;
- the Company's expectations involving its partnership with CCrest (including, without limitation, product testing, product development, studies of psilocybin, import licenses and the testing and development of the Company's microdosing capsules);
- the Company's plans for developing intellectual property, conducting scientific studies and scaling up its commercialization of its current and future products;
- the Company producing, distributing, and increasing its manufacturing capabilities with respect to the anticipated demand of its products upon the timelines indicated herein;
- the Company's plans to expand and develop its production facilities, distribution network and partnerships within the timelines provided herein;
- the Company creating and executing on its production, manufacturing and distribution plans in accordance with applicable laws and regulations;
- the Company's plans to expand operations of its mushroom production and distribution, and psilocybin production and sales across both North America and the European Union if and when regulations permit;

- the anticipated benefits and terms of the Company's partnerships with CCrest, and AEM, and the timelines thereto;
- the Company, in partnership with Radix Motion, building innovative technology (including, without limitation, to the Wisdom Truffle Moon) and increasing scientific data around microdosing that will provide the anticipated benefits to the Company and the Company's customers, within the timelines provided herein;
- the Company's intention to devote resources to the protection of its intellectual property rights, including by seeking and obtaining registered protections and developing and implementing standard operating procedures;
- the Company providing future information on its brands and product launches;
- the development of the Company's business, brands and future activities following the date of this MD&A;
- the realization of cost savings, synergies or benefits from the Company's recent and proposed acquisitions, and the Company's ability to successfully integrate the operations of any business acquired within the Company's business;
- the Company's plans to generate cash flow from operations and from financing activities;
- the Company remaining as fully vertically integrated with respect to its truffle operations in the Netherlands;
- the Company's plans to develop the Mushroom Facilities on its Peterborough Farm under the anticipated timelines and budgets and the anticipated benefits to the Company, its partners, and clients;
- the Company hitting its forecasted revenue and sales projections for its current fiscal year and beyond;
- the stated terms and goals with respect to the Company's engagement of consultants and advisors;
- the Company's continuation of the expected product distribution plans and timelines for MISTERCAP products;
- the interpretation of results of stability tests for psilocybin microdosing capsules and determination of their shelf life; and
- the distribution and promotion of homogenized psilocybin microdosing capsules and the engagement of medical advisors for the same.

Forward looking statements included throughout this MD&A are based on a number of factors and assumptions which have been used to develop such statements and information, but which may prove to be incorrect, including, but not limited to, assumptions about:

- current and future members of the Company's management abiding by the business objectives and strategies from time to time established by the Company;
- the Company's ability to capitalize on future growth prospects and intentions to pursue one or more viable business opportunities;
- the Company retaining and supplementing its Board and management, or otherwise, engaging consultants and advisors having knowledge of the industries (or segments thereof) within which the Company may from time to time participate;
- the Company having sufficient working capital and the ability to obtain the financing required to develop and continue its business and operations;

- the Company's ability to execute on its business plan and obtain, maintain, and renew or extend, applicable licenses and authorizations, including the timing and impact of the receipt thereof;
- the Company continuing to attract, develop, motivate and retain highly qualified and skilled consultants and/or employees, as the case may be;
- no adverse changes will be made in the jurisdictions in which the Company conducts business and any other jurisdiction in which the Company may conduct business in the future;
- the Company's ability to carry out its business and future activities following the date of this MD&A;
- the Company's ability to make accurate forecasts with respect to its expectations relating to market size and anticipated growth in the jurisdictions within which the Company may from time to time operate or contemplate future operations;
- the Company's ability to make accurate forecasts with respect to its expectations on economic, business, regulatory and/or competitive factors related to the Company and the industries within which it operates generally;
- the Company's ability, in partnership with Radix Motion, to build innovative technologies;
- general, economic, financial, market, regulatory and political conditions, including the impact of COVID-19, will not negatively affect the Company or its business;
- the continuous demand for the Company's current and future product offerings;
- the Company effectively managing anticipated and unanticipated costs;
- the Company executing on its business strategy as anticipated;
- the Company generating cash flow from operations, including, where applicable, through the distribution and sale of its current and future products;
- the Company conducting its operations in a safe, efficient and effective manner;
- the Company's ability to grow its online retail portfolio and brick-and-mortar store locations;
- the Company initiating the development, production, distribution, promotion and sale of its products within the timelines provided herein;
- continued approval of the Company's activities by the relevant governmental and/or regulatory authorities;
- product testing yielding favourable results;
- the Company expanding its production and distribution network and entering into and maintaining pertinent partnerships;
- the Company finding viable opportunities to expand its business to new jurisdictions;
- the Company's ability to launch, manufacture, distribute and sell all the products on the terms and timelines outlined herein;
- the Company's ability to remain as fully vertically integrated with respect to its truffle operations in the Netherlands;
- the Company's ability to carry out its plans to develop the Mushroom Facilities on its the Peterborough Farm under the anticipated timelines and budgets and the anticipated benefits to the Company, its partners, and clients;
- the Company's ability to carry out the stated terms and goals with respect to its engagement of consultants and advisors;

- the Company devoting resources to the protection of its intellectual property rights;
- the accuracy of the Company's interpretation of results of stability tests for psilocybin microdosing capsules and determination of shelf life; and
- the Company's ability to realize upon its plans for the distribution and promotion of homogenized psilocybin microdosing capsules and the engagement of medical advisors for the same.

Further, readers are cautioned that forward looking statements involve known and unknown risks, uncertainties and other factors (many of which are beyond the Company's ability to predict or control) that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. In particular, the Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of the risk factors set forth below and elsewhere in this MD&A, which should not be considered exhaustive:

- the Company's inability to attract and retain qualified members of management to grow the business and/or its operations;
- unanticipated changes in general economic, business and market conditions or in applicable laws;
- the Company's inability to capitalize on future growth prospects and intentions to pursue one or more viable business opportunities;
- the Company's inability to execute on its business plan and obtain, maintain, and renew or extend, applicable licenses and authorizations, including the timing and impact of the receipt thereof;
- the impact of the publications of inaccurate or unfavourable research by securities analysts or other third parties;
- the Company's inability to carry out its business and future activities following the date of this MD&A;
- the Company's inability to make accurate forecasts with respect to its expectations relating to market size and anticipated growth in the jurisdictions within which the Company may from time to time operate or contemplate future operations;
- the Company's inability to make accurate forecasts with respect to its expectations on economic, business, regulatory and/or competitive factors related to the Company and the industries within which it operates generally;
- the Company's inability, in partnership with Radix Motion, to build innovative technologies;
- the Company's inability to execute objectives, including expanding its production and distribution networks and entering into and/or maintaining requisite partnerships within the timelines outlined herein or at all;
- the Company's failure to complete future acquisitions or enter into strategic business relationships;
- unanticipated changes in the industries, regulations and jurisdictions within which the Company may from time to time conduct its business and operations, including the Company's inability to respond or adapt to such changes;
- the Company's inability to secure or maintain favourable lease arrangements or the required authorizations necessary to conduct the business and operations and meet its targets;

- the Company's inability to effectively manage unanticipated costs and expenses, including costs and expenses associated with product recalls and judicial or administrative proceedings against the Company;
- the Company will be unable to grow its online retail and brick-and-mortar store portfolio;
- fluctuation in foreign exchange or interest rates;
- the Company's inability to meet its performance, business objectives and/or milestones and/or realize the effects of, on the anticipated timing of or at all, in connection with, the execution or achievement of such objectives and milestones
- the Company's inability to produce and distribute its product offerings and capture market share;
- liabilities inherent in the operations of the Company as a participant in the mushroom industry;
- the Company's inability to develop its business, brands and future activities following the date of this MD&A;
- the Company's inability to remain as fully vertically integrated with respect to its truffle operations in the Netherlands;
- the Company's inability to carry out its plans to develop and staff the Mushroom Facilities on it's the Peterborough Farm under the anticipated timelines and budgets and the anticipated benefits to the Company, its partners, and clients;
- the Company's manufacturers of the Peterborough Farm building and related production equipment inability to meet anticipated delivery and installation timelines and the costs related to the delay;
- the Company devoting resources to the protection of its;
- the Company's inability to devote resources to the protection of its intellectual property rights, including by seeking and obtaining registered protections and developing and implementing standard operating procedures;
- the Company's ability to carry out the stated terms and goals with respect to its engagement of consultants and advisors;
- the Company's ability to launch, manufacture, distribute and sell all the products on the terms and timelines outlined herein;
- the inaccuracy of the Company's interpretation of results of stability tests for psilocybin microdosing capsules and determination of shelf life; and
- the Company's inability to realize upon its plans for the distribution and promotion of homogenized psilocybin microdosing capsules and the engagement of medical advisors for the same.

Readers are cautioned that the foregoing lists of factors are not exhaustive. These FLS speak only as of the date of this MD&A or as of the date specified in the documents incorporated by reference into this MD&A and the Company does not assume any obligation to publicly update or revise them to reflect new events or circumstances, except as may be required pursuant to applicable securities laws.

The FLS contained in this MD&A and the documents incorporated by reference herein are expressly qualified by this cautionary statement. The actual results could differ materially from those anticipated in these forward-looking statements as a result of the risk factors set forth below

and elsewhere in this MD&A. As such, forward-looking statements included in this MD&A and in the documents incorporated by reference into this MD&A should not be unduly relied upon.

CAUTIONARY NOTE REGARDING FUTURE ORIENTED FINANCIAL INFORMATION

This MD&A and the documents incorporated by reference herein may contain future oriented financial information ("FOFI") within the meaning of Canadian securities legislation, about prospective results of operations, financial position or cash flows, based on assumptions about future economic conditions and courses of action, which FOFI is not presented in the format of a historical balance sheet, income statement or cash flow statement. The FOFI has been prepared by management to provide an outlook of the Company's activities and results and has been prepared based on a number of assumptions including the assumptions discussed under the heading above entitled "Caution Regarding Forward Looking Information And Cautionary Statements" and assumptions with respect to the costs and expenditures to be incurred by the Company, capital expenditures and operating costs, taxation rates for the Company and general and administrative expenses. Management does not have, or may not have had at the relevant date, firm commitments for all of the costs, expenditures, prices or other financial assumptions which may have been used to prepare the FOFI or assurance that such operating results will be achieved and, accordingly, the complete financial effects of all of those costs, expenditures, prices and operating results are not, or may not have been at the relevant date of the FOFI, objectively determinable.

Importantly, the FOFI contained in this MD&A and the documents incorporated by reference herein, are, or may be, based upon certain additional assumptions that management believes to be reasonable based on the information currently available to management, including, but not limited to, assumptions about: (i) the future pricing for the Company's products, (ii) the future market demand and trends within the jurisdictions in which the Company may from time to time conduct the Company's business, (iii) the Peterborough Farm's expected revenues of approximately \$80,000 per week upon being operational, (iv) the estimated revenue run rate of \$16.0 to \$17.0 million per annum when the Peterborough Farm becomes operational and the resulting strong profit margins and cash flow from operations; (v) the estimated cost of building the Mushroom Facilities at \$12.0 million; and (vi) the expectations that the AEM farm in New Brunswick generating approximately \$24,000 and \$30,000 of revenue per week being based on the ability of the AEM farm to continue to produce 4,000 to 5,000 pounds of shiitake mushrooms per week and for such yield to translate into the expected revenues of \$24,000 to \$30,000 per week is dependent on certain assumptions that management of the Company believes to be reasonable based on the information currently available to management, including the following assumptions: (a) the good working order of all equipment used for the production and distribution of the shiitake mushrooms and other exotic mushrooms) (b) the growth process presently employed by the AEM farm in respect of its production schedule being adequate to support the anticipated yield of mushrooms (c) the hiring of the necessary amount of employees who cultivate, harvest, package and deliver to market the mushrooms on a timely basis are able to continue to do so; (d) the historical yield of AEM farm provides an adequate basis for the production of new mushrooms; (e) the current wholesale market for shiitake mushrooms and other exotic mushrooms will be able to absorb the additional production; (f) the forecasted sales and projected revenue streams of the Peterborough

Farm; (g) and the Company's continued mushroom sales of current products and anticipated growth in current and future mushroom products in Ontario and North America.

The FOFI or financial outlook contained in this MD&A do not purport to present the Company's financial condition in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, and there can be no assurance that the assumptions made in preparing the FOFI will prove accurate. The actual results of operations of the Company and the resulting financial results will likely vary from the amounts set forth in the analysis presented in any such document, and such variation may be material (including due to the occurrence of unforeseen events occurring subsequent to the preparation of the FOFI). The Company and management believe that the FOFI has been prepared on a reasonable basis, reflecting management's best estimates and judgments as at the applicable date. However, because this information is highly subjective and subject to numerous risks including the risks discussed under the heading above entitled "Cautionary Note Regarding Forward-Looking Statements" and under the heading "Risk Factors" in the Company's public disclosures, FOFI or financial outlook within this in this MD&A should not be relied on as necessarily indicative of future results.

Readers are cautioned not to place undue reliance on the FOFI, or financial outlook contained in this MD&A. Except as required by Canadian securities laws, the Company does not intend, and does not assume any obligation, to update such FOFI.